CDK1-derived competitive peptide

CDK1-derived competitive peptide is a preclinical synthetic peptide designed to disrupt the interaction between apolipoprotein J (ApoJ/clusterin) and cyclin-dependent kinase 1 (CDK1) [1027]. ApoJ acts as a stress-induced molecular chaperone that binds to the C-lobe of CDK1, disrupting the protective TRIM28-CDK1 interaction and promoting ubiquitin-dependent proteasomal degradation of CDK1, which delays G2/M cell-cycle progression [1027]. By mimicking the binding region of CDK1, the competitive peptide binds to ApoJ, preventing it from destabilizing CDK1 [1027]. This preserves CDK1 protein abundance and enhances liver regeneration [1027]. Developed by researchers at The First Affiliated Hospital of Guangxi Medical University, the peptide has shown efficacy in enhancing liver regeneration in hepatectomized and carbon tetrachloride (CCl4)-induced liver injury mouse models [1027].